Benefits associated with the complex action of vinpocetine in the light of experimental and clinical studies Review article
Article Sidebar
Published:
Mar 31, 2013
Keywords:
vinpocetine, dementia, ischemic stroke
Main Article Content
Abstract
In the paper the complex action of vinpocetine was presented and review of the experimental and clinical studies were conducted. Particular attention was given concerning the efficacy and safety profile of the drug. The most interesting data come from randomized trial, in which the authors especially pay attention to the need to carry out clinical trials with high reliability, involving a large groups of patients undergoing long-term drug therapy, even in the higher dose of drug, than the currently registered and used in the clinical practice, because too low dose may be the reason of subclinical effect of the drug.
Article Details
How to Cite
Zaremba, M., & Postuła , M. (2013). Benefits associated with the complex action of vinpocetine in the light of experimental and clinical studies. Medycyna Faktow (J EBM), 6(1(18), 30-41. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2425
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Lorincz C., Szasz K., Kisfaludy L.: The synthesis of ethyl apovincaminate. Arzneimittelforschung 1976; 26: 1907.
2. Vinpocetine. Altern. Med. Rev. 2002; 7: 240-243.
3. Karpati E., Biro K., Kukorelli T.: [Investigation of vasoactive agents with indole skeletons at Richter Ltd]. Acta Pharm. Hung. 2002; 72: 25-36.
4. Bereczki D., Fekete I.: A systematic review of vinpocetine therapy in acute ischaemic stroke. Eur. J. Clin. Pharmacol. 1999; 55: 349-352.
5. Hadjiev D., Yancheva S.: Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency. Arzneimittelforschung 1976; 26: 1947-1950.
6. Ribari O., Zelen B., Kollar B.: Ethyl apovincaminate in the treatment of sensorineuronal impairment of hearing. Arzneimittelforschung 1976; 26: 1977-1980.
7. Szobor A., Klein M.: Ethyl apovincaminate therapy in neurovascular diseases. Arzneimittelforschung 1976; 26: 1984-1989.
8. Kaham A., Olah M.: Use of ethyl apovincaminate in ophthalmological therapy. Arzneimittelforschung 1976; 26: 1969-1972.
9. Nosalova V., Machova J., Babulova A.: Protective action of vinpocetine against experimentally induced gastric damage in rats. Arzneimittelforschung 1993; 43: 981-985.
10. Miyata N., Yamaura H., Tanaka M., Muramatsu M., Tsuchida K., Okuyama S., Otomo S.: Effects of VA-045, a novel apovincaminic acid derivative, on isolated blood vessels: cerebroarterial selectivity. Life Sci. 1993; 52: 181-186.
11. Sitges M., Galván E., Nekrassov V.: Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosome. Neurochem. Int. 2005; 46: 533-540.
12. Lynch J.J., Yu S.P., Canzoniero L.M. et al.: Sodium channel blocker reduce oxygen-glucose deprivation – induced cortical neuron injury when combined with glutamate receptor antagonists. J. Pharmacol. Exp. Ther. 1995; 273: 554-560.
13. Tárnok K., Kiss E., Luiten P.G., Nyakas C., Tihanyi K., Schlett K., Eisel U.L.: Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochem. Int. 2008; 53: 289-295.
14. Stolc S.: Indole derivatives as neuroprotectants. Life Sci. 1999; 65: 1943-1950.
15. Hagiwara M., Endo T., Hidaka H.: Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem. Pharmacol. 1984; 33: 453-457.
16. Truss M.C., Uckert S., Stief C.G., Forssmann W.G., Jonas U.: Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol. Res. 1996; 24: 129-134.
17. Jeon K.I., Xu X., Aizawa T., Lim J.H., Jono H., Kwon D.S., Abe J. et al.: Vinpocetine inhibits NF-кB dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl. Acad. Sci. USA 2010; 107: 9795-9800.
18. Matsukawa M., Ogawa M., Nakadate K., Maeshima T., Ichitani Y., Kawai N.: Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Neurosci. Lett. 1997; 230: 13-16.
19. Shibuya T., Sato K.: Effects of vinpocetine on experimental brain ischemia, histological study of brain monomines. Igaku No Ayumi 1986; 139: 217-219.
20. Trejo F., Nekrassov V., Sitges M.: Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings. Brain Res. 2001; 909: 59-67.
21. Milusheva E., Sperlagh B., Kiss B., Szporny L., Pásztor E., Papasova M., Vizi E.S.: Inhibitory effect of hypoxic condition on acetylcholine release is partly due to the effect of adenosine released from the tissue. Brain Res. Bull. 1990; 24: 369-373.
22. Kuzuya F., Osawa M., Maruyama S.: Effects of vinpocetine on blood viscosity and platelet aggregability. Today’s Therapy Trends 1985; 1: 21-29.
23. Csillik B., Mihály A., Knyihár-Csillik E.: Antinociceptive effect of vinpocetine – a comprehensive survey. Ideggyogy Sz. 2010; 63: 185-192.
24. DeNoble V.J., Repetti S.J., Gelpke L.W., Wood L.M., Keim K.L.: Vinpocetine: nootropic effects on scopolamineinduced and hypoxia-induced retrieval deficits of a step-through passive avoidance response in rats. Pharmacol. Biochem. Behav. 1986; 24: 1123-1128.
25. Nyakas C., Felszeghy K., Szabó R., Keijser J.N., Luiten P.G., Szombathelyi Z., Tihanyi K.: Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model. CNS Neurosci. Ther. 2009; 15: 89-99.
26. Deshmukh R., Sharma V., Mehan S., Sharma N., Bedi K.L.: Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine – a PDE1 inhibitor. Eur. J. Pharmacol. 2009; 620: 49-56.
27. Pereira C., Agostinho P., Moreira P.I., Duarte A.I., Santos M.S., Oliveira C.R.: Neuroprotection strategies: effect of vinpocetine in vitro oxidative stress models (Portuguese). Acta Med. Port. 2003; 16: 401-406.
28. Pereira C., Agostinho P., Oliveira C.R.: Vinpocetine attenuates the metabolic dysfunction induced by amyloid betapeptides in PC12 cells. Free Radic. Res. 2000; 33: 497-506.
29. Thal L.J., Salmon D.P., Lasker B., Bower D., Klauber M.R.: The safety and lack of efficacy of vinpocetine in Alzheimer’s disease. J. Am. Geriatr. Soc. 1989; 37: 515-520.
30. Szatmari S.Z., Whitehouse P.J.: Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst. Rev. 2003; 1: CD003119.
31. Valikovics A.: [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007; 60: 301-310.
32. Tohgi H., Sasaki K., Chiba K., Nozaki Y.: Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneimittelforschung 1990; 40: 640-643.
33. Balestreri R., Fontana L., Astengo F.: A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J. Am. Geriatr. Soc. 1987; 35: 425-430.
34. Valikovics A., Csányi A., Németh L.: Study of the effects of vinpocetin on cognitive functions. Ideggyogy Sz. 2011; 64: 115-120.
35. Olpe H.R., Steinmann M.W., Jones R.S.G.: Locus coeruleus as a target for psychogeriatric agents. Ann. N.Y. Acad. Sci. 1985; 444: 399-405.
36. Gaal L., Molnar P.: Effect of vinpocetine on noradrenergic neurons in rat locus coeruleus. Eur. J. Pharmacol. 1990; 187: 537-539.
37. McDaniel M.A., Maier S.F., Einstein G.O.: Brain-specific nutrients: a memory cure? Nutrition 2003; 19: 957-975.
38. Subhan Z., Hindmarch I.: Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur. J. Clin. Pharmacol. 1985; 28: 567-571.
39. Polich J., Gloria R.: Cognitive effects of a Ginkgo biloba/vinpocetine compound in normal adults: systematic assessment of perception, attention and memory. Hum. Psychopharmacol. 2001; 16: 409-416.
40. Dutov A.A., Tolpyshev B.A., Karpov V.N., Petrov A.P.: [Effect of Cavinton on convulsions caused by chemical substances]. Farmakol. Toksikol. 1986; 49: 22-25.
41. Nekrassov V., Sitges M.: Vinpocetine inhibits the epileptic cortical activity and auditory alterations induced by pentylenetetrazole in the guinea pig in vivo. Epilepsy Res. 2004; 60: 63-71.
42. Sitges M., Nekrassov V.: Vinpocetine prevents 4-aminopyridine-induced changes in the EEG, the auditory brainstem responses and hearing. Clin. Neurophysiol. 2004; 115: 2711-2717.
43. Sitges M., Guarneros A., Nekrassov V.: Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: comparison with the Na+ channel-mediated release. Neuropharmacol. 2007; 53: 854-862.
44. Dutov A.A., Tolpyshev B.A., Petrov A.P., Gladun V.N.: [Use of cavinton in epilepsy]. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1986; 86: 850-855.
45. Dutov A.A., Gal’tvanitsa G.A., Volkova V.A., Sukhanova O.N., Lavrishcheva T.G., Petrov A.P.: [Cavinton in the prevention of the convulsive syndrome in children after birth injury]. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1991; 91: 21-22.
46. Otroshchenko N.: [Psychopharmacotherapy in combine treatment of depressive disorders in patients with brain pathology affected by the Chernobyl Atomic Electric Power Station accident]. Lik. Sprava. 2000; 6: 8-10.
47. Hindmarch I., Fuchs H.H., Erzigkeit H.: Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int. Clin. Psychopharmacol. 1991; 6: 31-43.
48. Dézsi L., Kis-Varga I., Nagy J., Komlódi Z., Kárpáti E.: [Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke]. Acta Pharm. Hung. 2002; 72: 84-91.
49. Zhou X., Dong X., Crona J., Maguire M., Priestley T.: Vinpocetine is a potent blocker of rat NaV1.8 Tetrodotoxin-Resistant sodium Channels. JPET 2003; 306: 498-504.
50. Zelles T., Franklin L., Koncz I., Lendvai B., Zsilla G.: The nootropic drug vinpocetine inhibits veratridine – induced [Ca2+] increase in rat hippocampal CA1 pyramidal cells. Neurochem. Res. 2001; 26: 1095-1100.
51. Bonoczk P., Gulyas B., Adam-Vizi V., Nemes A., Karpati E., Kiss B., Kapas M., Szantay C., Koncz I., Zelles T., Vas A.: Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine. Brain Research Bulletin 2000; 53: 245-254.
52. Katsuta K., Umemura K., Ueyama N., Matsuoka N.: Pharmacological evidence for a correlation between hippocampal CA1 cell damage and hyperlocomotion following global cerebral ischemia in gerbils. Eur. J. Pharmacol. 2003; 467: 103-109.
53. Maslarova J., Nikolov R.: Antihypoxic effect of vinpocetine. Works of the Chemical Pharmaceutical Research Institute, 1999; XIX: 175-182.
54. Lamar J.C., Poignet H., Beaughard M.: Calcium antagonist activity of vinpocetine and vincamine in several models of cerebral ischemia. Drug. Develop. Res. 1988; 14: 297-304.
55. Rischke R., Krieglstein J.: Protective effect of vinpocetine against brain damage caused by ischemia. Jpn J. Pharmacol. 1991; 56: 349-356.
56. Krieglstein J., Rischke R.: Vinpocetine increases the neuroprotective effect of adenosine in vitro. Eur. J. Pharmacol. 1991; 205: 7-10.
57. Szmolenszky T., Török B.: Effect of ethyl apovincaminate on cerebral, cardiac and renal flow rate in dogs in the course of administration. Arzneimittelforschung 1976; 26: 1914-1917.
58. Romodanov A.P., Potapov A.I.: [The dynamic changes in the regional volumetric cerebral blood flow and local vascular reactivity in acute craniocerebral trauma in animals with alloxan diabetes]. Zh. Vopr. Neirokhir. Im. N.N. Burdenko 1990; 3: 19-22.
59. Hadjiev D.: Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogy Sz. 2003; 56: 166-172.
60. Feigin V.L., Doronin B.M., Popova T.F. et al.: Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur. J. Neurol. 2001; 8: 81-85.
61. Bereczki D., Fekete I.: Vinpocetine for acute ischaemic stroke. Cochrane Database Syst. Rev. 2000; 2: CD000480.
62. Solti F., Iskum M., Czakó E.: Effect of ethyl apovincaminate on the cerebral circulation. Studies in patients with obliterative cerebral arterial disease. Arzneimittelforschung 1976; 26: 1945-1947.
63. Miyazaki M.: The effect of cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiology 1995; 46: 53-58.
64. Hadjiev D., Yancheva S.: Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency. Arzneimittelforschung 1976; 26: 1947-1950.
65. Feher G., Koltai K., Kesmarky G., Horvath B., Toth K., Komoly S., Szapary L.: Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine 2009; 16: 111-117.
66. Szapáry L., Horváth B., Alexy T., Márton Z., Késmárky G., Szóts M., Nagy F. et al.: [Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease]. Orv. Hetil. 2003; 144: 973-978.
67. Hayakawa M.: Comparative efficacy of vinpocetine, pentoxifylline and nicergoline on red blood cell deformability. Arzneimittelforschung 1992; 42: 108-110.
68. Burtsev E.M., Savkov V.S., Shprakh V.V., Burtsev M.E.: [10-years experience with using Cavinton in cerebrovascular disorders]. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1992; 92: 56-60.
69. Bereczki D., Fekete I.: Vinpocetine for acute ischemic stroke. Stroke 2008; 39: 2404-2405.
70. Salvemini D., Misko T.P., Masferrer J.L. et al.: Nitric oxide activates cyclooxygenase enzymes. Proc. Natl. Acad. Sci. USA 1993; 90: 7240-7244.
71. Olah V.A., Balla G., Balla J., Szabolcs A., Karmazsin L.: An in vitro study of the hydroxyl scavenger effect of Cavinton. Acta Paediatr. Hung. 1990; 30: 309-316.
72. Santos M., Duarte A., Moreira P., Oliveira C.: Synaptosomal response to oxidative stress: effect of vinpocetine. Free Radic. Res. 2000; 32: 57-66.
73. Gabryel B., Adamek M., Pudelko A., Malecki A., Trzeciak H.: Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 2002; 23: 19-31.
74. Kolarov G., Orbetsova M., Nalbanski B. et al.: Complex effects of cavinton on climacteric symptoms. Akush. Ginekol. 2001; 42: 37-41.
75. Kiss E.: Adjuvant effect of cavinton in the treatment of climacteric symptoms. Ther. Hung. 1990; 38: 170-173.
76. Nekrassov V., Sitges M.: Vinpocetine protects from aminoglycoside antibiotic-induced hearing loss in guinea pig in vivo. Brain Res. 2000; 868: 222-229.
77. Maliavina U.S., Ovchinnikov I.U.M., Fasenko V.P., Maliev B.M., Kalinina M.V., Dadasheva B.B.: [Cavinton prevention of neurosensory hypoacousis in patients with different forms of tuberculosis]. Vestn. Otorinolaringol. 2003; 3: 35-40.
78. Jasper A.: Action of cavinton on hearing defects of different origin. Hung. Med. 1978; 26: 181-184.
79. Truss M., Stief C., Uckert S. et al.: Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J. Urol. 2001; 19: 344-350.
80. Truss M., Stief C., Uckert S. et al.: Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J. Urol. 2000; 18: 439-443.
81. Csillik B., Mihály A., Knyihár-Csillik E.: Antinociceptive effect of vinpocetine – a comprehensive survey. Ideggyogy Sz. 2010; 63: 185-192.
82. Lohmann A., Dingler E., Sommer W., Schaffler K., Wober W., Schmidt W.: Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung 1992; 42, 914-917.
83. Miskolczi P., Korma K., Polgar M., Vereczkey L.: Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur. J. Drug. Metab. Pharmacokinet. 1990; 15: 1-5.
84. Vereczkey L.: Pharmacokinetics and metabolism of vincamine and related compounds. Eur. J. Drug. Metab. Pharmacokinet. 1985; 10: 89-103.
85. Skoromets A.A., Tanashian M.M., Chukanova E.I., Petrova E.A., Spirin N.N., Nikonov A.A., Peverennova I.E., Levin I.I.: [A multicenter program on assessment of efficacy and safety of a new therapeutic scheme for patients with chronic cerebrovascular insufficiency]. Zh. Nevrol. Psikhiatr. Im. S.S. Korsakova 2009; 109: 44-48.
86. Szakáll S., Boros I., Balkay L., Emri M., Fekete I., Kerényi L., Lehel S. et al.: Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: A PET study. J. Neuroimaging. 1998; 8: 197-204.
87. Charakterystyka Produktu Leczniczego Cavinton Forte 10 mg, tabletki; z dnia 23.04.2008.
88. Shimizu Y., Saitoh K., Nakayama M.: Agranulocytosis induced by vinpocetine. Medicine Online.
89. Akopov S.E., Gabrielian E.S.: Effects of aspiryn, dipyramidole, nifedipine and cavinton chich act on platet aggregation induced by diffrent aggregating agents alone and in combination. Eur. J. Clin. Pharmacol. 1992; 42: 257-259.
90. Hitzenberger G., Schmid R., Braun W., Grandt R.: Vinpocetine therapy does not change imipramine pharmacokinetics in man. Int. J. Clin. Pharmacol. Ther. Toxicol. 1990; 28: 99-104.
91. Grandt R., Braun W., Schulz H.U., Lührmann B., Frercks H.J.: Glibenclamide steady state plasma levels during concomitant vinpocetine administration in type II diabetic patients. Arzneimittelforschung 1989; 39: 1451-1454.
92. Storm G., Oosterhuis B., Sollie F.A.E., Visscher H.W., Sommer W., Beitinger H., Jonkman J.H.G.: Lack of pharmacokinetic interaction between vinpocetine and oxazepam. Br. J. Clin. Pharmcol. 1994; 38: 143-146.
2. Vinpocetine. Altern. Med. Rev. 2002; 7: 240-243.
3. Karpati E., Biro K., Kukorelli T.: [Investigation of vasoactive agents with indole skeletons at Richter Ltd]. Acta Pharm. Hung. 2002; 72: 25-36.
4. Bereczki D., Fekete I.: A systematic review of vinpocetine therapy in acute ischaemic stroke. Eur. J. Clin. Pharmacol. 1999; 55: 349-352.
5. Hadjiev D., Yancheva S.: Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency. Arzneimittelforschung 1976; 26: 1947-1950.
6. Ribari O., Zelen B., Kollar B.: Ethyl apovincaminate in the treatment of sensorineuronal impairment of hearing. Arzneimittelforschung 1976; 26: 1977-1980.
7. Szobor A., Klein M.: Ethyl apovincaminate therapy in neurovascular diseases. Arzneimittelforschung 1976; 26: 1984-1989.
8. Kaham A., Olah M.: Use of ethyl apovincaminate in ophthalmological therapy. Arzneimittelforschung 1976; 26: 1969-1972.
9. Nosalova V., Machova J., Babulova A.: Protective action of vinpocetine against experimentally induced gastric damage in rats. Arzneimittelforschung 1993; 43: 981-985.
10. Miyata N., Yamaura H., Tanaka M., Muramatsu M., Tsuchida K., Okuyama S., Otomo S.: Effects of VA-045, a novel apovincaminic acid derivative, on isolated blood vessels: cerebroarterial selectivity. Life Sci. 1993; 52: 181-186.
11. Sitges M., Galván E., Nekrassov V.: Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosome. Neurochem. Int. 2005; 46: 533-540.
12. Lynch J.J., Yu S.P., Canzoniero L.M. et al.: Sodium channel blocker reduce oxygen-glucose deprivation – induced cortical neuron injury when combined with glutamate receptor antagonists. J. Pharmacol. Exp. Ther. 1995; 273: 554-560.
13. Tárnok K., Kiss E., Luiten P.G., Nyakas C., Tihanyi K., Schlett K., Eisel U.L.: Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochem. Int. 2008; 53: 289-295.
14. Stolc S.: Indole derivatives as neuroprotectants. Life Sci. 1999; 65: 1943-1950.
15. Hagiwara M., Endo T., Hidaka H.: Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem. Pharmacol. 1984; 33: 453-457.
16. Truss M.C., Uckert S., Stief C.G., Forssmann W.G., Jonas U.: Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol. Res. 1996; 24: 129-134.
17. Jeon K.I., Xu X., Aizawa T., Lim J.H., Jono H., Kwon D.S., Abe J. et al.: Vinpocetine inhibits NF-кB dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl. Acad. Sci. USA 2010; 107: 9795-9800.
18. Matsukawa M., Ogawa M., Nakadate K., Maeshima T., Ichitani Y., Kawai N.: Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Neurosci. Lett. 1997; 230: 13-16.
19. Shibuya T., Sato K.: Effects of vinpocetine on experimental brain ischemia, histological study of brain monomines. Igaku No Ayumi 1986; 139: 217-219.
20. Trejo F., Nekrassov V., Sitges M.: Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings. Brain Res. 2001; 909: 59-67.
21. Milusheva E., Sperlagh B., Kiss B., Szporny L., Pásztor E., Papasova M., Vizi E.S.: Inhibitory effect of hypoxic condition on acetylcholine release is partly due to the effect of adenosine released from the tissue. Brain Res. Bull. 1990; 24: 369-373.
22. Kuzuya F., Osawa M., Maruyama S.: Effects of vinpocetine on blood viscosity and platelet aggregability. Today’s Therapy Trends 1985; 1: 21-29.
23. Csillik B., Mihály A., Knyihár-Csillik E.: Antinociceptive effect of vinpocetine – a comprehensive survey. Ideggyogy Sz. 2010; 63: 185-192.
24. DeNoble V.J., Repetti S.J., Gelpke L.W., Wood L.M., Keim K.L.: Vinpocetine: nootropic effects on scopolamineinduced and hypoxia-induced retrieval deficits of a step-through passive avoidance response in rats. Pharmacol. Biochem. Behav. 1986; 24: 1123-1128.
25. Nyakas C., Felszeghy K., Szabó R., Keijser J.N., Luiten P.G., Szombathelyi Z., Tihanyi K.: Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model. CNS Neurosci. Ther. 2009; 15: 89-99.
26. Deshmukh R., Sharma V., Mehan S., Sharma N., Bedi K.L.: Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine – a PDE1 inhibitor. Eur. J. Pharmacol. 2009; 620: 49-56.
27. Pereira C., Agostinho P., Moreira P.I., Duarte A.I., Santos M.S., Oliveira C.R.: Neuroprotection strategies: effect of vinpocetine in vitro oxidative stress models (Portuguese). Acta Med. Port. 2003; 16: 401-406.
28. Pereira C., Agostinho P., Oliveira C.R.: Vinpocetine attenuates the metabolic dysfunction induced by amyloid betapeptides in PC12 cells. Free Radic. Res. 2000; 33: 497-506.
29. Thal L.J., Salmon D.P., Lasker B., Bower D., Klauber M.R.: The safety and lack of efficacy of vinpocetine in Alzheimer’s disease. J. Am. Geriatr. Soc. 1989; 37: 515-520.
30. Szatmari S.Z., Whitehouse P.J.: Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst. Rev. 2003; 1: CD003119.
31. Valikovics A.: [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007; 60: 301-310.
32. Tohgi H., Sasaki K., Chiba K., Nozaki Y.: Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneimittelforschung 1990; 40: 640-643.
33. Balestreri R., Fontana L., Astengo F.: A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J. Am. Geriatr. Soc. 1987; 35: 425-430.
34. Valikovics A., Csányi A., Németh L.: Study of the effects of vinpocetin on cognitive functions. Ideggyogy Sz. 2011; 64: 115-120.
35. Olpe H.R., Steinmann M.W., Jones R.S.G.: Locus coeruleus as a target for psychogeriatric agents. Ann. N.Y. Acad. Sci. 1985; 444: 399-405.
36. Gaal L., Molnar P.: Effect of vinpocetine on noradrenergic neurons in rat locus coeruleus. Eur. J. Pharmacol. 1990; 187: 537-539.
37. McDaniel M.A., Maier S.F., Einstein G.O.: Brain-specific nutrients: a memory cure? Nutrition 2003; 19: 957-975.
38. Subhan Z., Hindmarch I.: Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur. J. Clin. Pharmacol. 1985; 28: 567-571.
39. Polich J., Gloria R.: Cognitive effects of a Ginkgo biloba/vinpocetine compound in normal adults: systematic assessment of perception, attention and memory. Hum. Psychopharmacol. 2001; 16: 409-416.
40. Dutov A.A., Tolpyshev B.A., Karpov V.N., Petrov A.P.: [Effect of Cavinton on convulsions caused by chemical substances]. Farmakol. Toksikol. 1986; 49: 22-25.
41. Nekrassov V., Sitges M.: Vinpocetine inhibits the epileptic cortical activity and auditory alterations induced by pentylenetetrazole in the guinea pig in vivo. Epilepsy Res. 2004; 60: 63-71.
42. Sitges M., Nekrassov V.: Vinpocetine prevents 4-aminopyridine-induced changes in the EEG, the auditory brainstem responses and hearing. Clin. Neurophysiol. 2004; 115: 2711-2717.
43. Sitges M., Guarneros A., Nekrassov V.: Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: comparison with the Na+ channel-mediated release. Neuropharmacol. 2007; 53: 854-862.
44. Dutov A.A., Tolpyshev B.A., Petrov A.P., Gladun V.N.: [Use of cavinton in epilepsy]. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1986; 86: 850-855.
45. Dutov A.A., Gal’tvanitsa G.A., Volkova V.A., Sukhanova O.N., Lavrishcheva T.G., Petrov A.P.: [Cavinton in the prevention of the convulsive syndrome in children after birth injury]. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1991; 91: 21-22.
46. Otroshchenko N.: [Psychopharmacotherapy in combine treatment of depressive disorders in patients with brain pathology affected by the Chernobyl Atomic Electric Power Station accident]. Lik. Sprava. 2000; 6: 8-10.
47. Hindmarch I., Fuchs H.H., Erzigkeit H.: Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int. Clin. Psychopharmacol. 1991; 6: 31-43.
48. Dézsi L., Kis-Varga I., Nagy J., Komlódi Z., Kárpáti E.: [Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke]. Acta Pharm. Hung. 2002; 72: 84-91.
49. Zhou X., Dong X., Crona J., Maguire M., Priestley T.: Vinpocetine is a potent blocker of rat NaV1.8 Tetrodotoxin-Resistant sodium Channels. JPET 2003; 306: 498-504.
50. Zelles T., Franklin L., Koncz I., Lendvai B., Zsilla G.: The nootropic drug vinpocetine inhibits veratridine – induced [Ca2+] increase in rat hippocampal CA1 pyramidal cells. Neurochem. Res. 2001; 26: 1095-1100.
51. Bonoczk P., Gulyas B., Adam-Vizi V., Nemes A., Karpati E., Kiss B., Kapas M., Szantay C., Koncz I., Zelles T., Vas A.: Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine. Brain Research Bulletin 2000; 53: 245-254.
52. Katsuta K., Umemura K., Ueyama N., Matsuoka N.: Pharmacological evidence for a correlation between hippocampal CA1 cell damage and hyperlocomotion following global cerebral ischemia in gerbils. Eur. J. Pharmacol. 2003; 467: 103-109.
53. Maslarova J., Nikolov R.: Antihypoxic effect of vinpocetine. Works of the Chemical Pharmaceutical Research Institute, 1999; XIX: 175-182.
54. Lamar J.C., Poignet H., Beaughard M.: Calcium antagonist activity of vinpocetine and vincamine in several models of cerebral ischemia. Drug. Develop. Res. 1988; 14: 297-304.
55. Rischke R., Krieglstein J.: Protective effect of vinpocetine against brain damage caused by ischemia. Jpn J. Pharmacol. 1991; 56: 349-356.
56. Krieglstein J., Rischke R.: Vinpocetine increases the neuroprotective effect of adenosine in vitro. Eur. J. Pharmacol. 1991; 205: 7-10.
57. Szmolenszky T., Török B.: Effect of ethyl apovincaminate on cerebral, cardiac and renal flow rate in dogs in the course of administration. Arzneimittelforschung 1976; 26: 1914-1917.
58. Romodanov A.P., Potapov A.I.: [The dynamic changes in the regional volumetric cerebral blood flow and local vascular reactivity in acute craniocerebral trauma in animals with alloxan diabetes]. Zh. Vopr. Neirokhir. Im. N.N. Burdenko 1990; 3: 19-22.
59. Hadjiev D.: Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogy Sz. 2003; 56: 166-172.
60. Feigin V.L., Doronin B.M., Popova T.F. et al.: Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur. J. Neurol. 2001; 8: 81-85.
61. Bereczki D., Fekete I.: Vinpocetine for acute ischaemic stroke. Cochrane Database Syst. Rev. 2000; 2: CD000480.
62. Solti F., Iskum M., Czakó E.: Effect of ethyl apovincaminate on the cerebral circulation. Studies in patients with obliterative cerebral arterial disease. Arzneimittelforschung 1976; 26: 1945-1947.
63. Miyazaki M.: The effect of cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiology 1995; 46: 53-58.
64. Hadjiev D., Yancheva S.: Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency. Arzneimittelforschung 1976; 26: 1947-1950.
65. Feher G., Koltai K., Kesmarky G., Horvath B., Toth K., Komoly S., Szapary L.: Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine 2009; 16: 111-117.
66. Szapáry L., Horváth B., Alexy T., Márton Z., Késmárky G., Szóts M., Nagy F. et al.: [Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease]. Orv. Hetil. 2003; 144: 973-978.
67. Hayakawa M.: Comparative efficacy of vinpocetine, pentoxifylline and nicergoline on red blood cell deformability. Arzneimittelforschung 1992; 42: 108-110.
68. Burtsev E.M., Savkov V.S., Shprakh V.V., Burtsev M.E.: [10-years experience with using Cavinton in cerebrovascular disorders]. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1992; 92: 56-60.
69. Bereczki D., Fekete I.: Vinpocetine for acute ischemic stroke. Stroke 2008; 39: 2404-2405.
70. Salvemini D., Misko T.P., Masferrer J.L. et al.: Nitric oxide activates cyclooxygenase enzymes. Proc. Natl. Acad. Sci. USA 1993; 90: 7240-7244.
71. Olah V.A., Balla G., Balla J., Szabolcs A., Karmazsin L.: An in vitro study of the hydroxyl scavenger effect of Cavinton. Acta Paediatr. Hung. 1990; 30: 309-316.
72. Santos M., Duarte A., Moreira P., Oliveira C.: Synaptosomal response to oxidative stress: effect of vinpocetine. Free Radic. Res. 2000; 32: 57-66.
73. Gabryel B., Adamek M., Pudelko A., Malecki A., Trzeciak H.: Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 2002; 23: 19-31.
74. Kolarov G., Orbetsova M., Nalbanski B. et al.: Complex effects of cavinton on climacteric symptoms. Akush. Ginekol. 2001; 42: 37-41.
75. Kiss E.: Adjuvant effect of cavinton in the treatment of climacteric symptoms. Ther. Hung. 1990; 38: 170-173.
76. Nekrassov V., Sitges M.: Vinpocetine protects from aminoglycoside antibiotic-induced hearing loss in guinea pig in vivo. Brain Res. 2000; 868: 222-229.
77. Maliavina U.S., Ovchinnikov I.U.M., Fasenko V.P., Maliev B.M., Kalinina M.V., Dadasheva B.B.: [Cavinton prevention of neurosensory hypoacousis in patients with different forms of tuberculosis]. Vestn. Otorinolaringol. 2003; 3: 35-40.
78. Jasper A.: Action of cavinton on hearing defects of different origin. Hung. Med. 1978; 26: 181-184.
79. Truss M., Stief C., Uckert S. et al.: Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J. Urol. 2001; 19: 344-350.
80. Truss M., Stief C., Uckert S. et al.: Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J. Urol. 2000; 18: 439-443.
81. Csillik B., Mihály A., Knyihár-Csillik E.: Antinociceptive effect of vinpocetine – a comprehensive survey. Ideggyogy Sz. 2010; 63: 185-192.
82. Lohmann A., Dingler E., Sommer W., Schaffler K., Wober W., Schmidt W.: Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung 1992; 42, 914-917.
83. Miskolczi P., Korma K., Polgar M., Vereczkey L.: Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur. J. Drug. Metab. Pharmacokinet. 1990; 15: 1-5.
84. Vereczkey L.: Pharmacokinetics and metabolism of vincamine and related compounds. Eur. J. Drug. Metab. Pharmacokinet. 1985; 10: 89-103.
85. Skoromets A.A., Tanashian M.M., Chukanova E.I., Petrova E.A., Spirin N.N., Nikonov A.A., Peverennova I.E., Levin I.I.: [A multicenter program on assessment of efficacy and safety of a new therapeutic scheme for patients with chronic cerebrovascular insufficiency]. Zh. Nevrol. Psikhiatr. Im. S.S. Korsakova 2009; 109: 44-48.
86. Szakáll S., Boros I., Balkay L., Emri M., Fekete I., Kerényi L., Lehel S. et al.: Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: A PET study. J. Neuroimaging. 1998; 8: 197-204.
87. Charakterystyka Produktu Leczniczego Cavinton Forte 10 mg, tabletki; z dnia 23.04.2008.
88. Shimizu Y., Saitoh K., Nakayama M.: Agranulocytosis induced by vinpocetine. Medicine Online.
89. Akopov S.E., Gabrielian E.S.: Effects of aspiryn, dipyramidole, nifedipine and cavinton chich act on platet aggregation induced by diffrent aggregating agents alone and in combination. Eur. J. Clin. Pharmacol. 1992; 42: 257-259.
90. Hitzenberger G., Schmid R., Braun W., Grandt R.: Vinpocetine therapy does not change imipramine pharmacokinetics in man. Int. J. Clin. Pharmacol. Ther. Toxicol. 1990; 28: 99-104.
91. Grandt R., Braun W., Schulz H.U., Lührmann B., Frercks H.J.: Glibenclamide steady state plasma levels during concomitant vinpocetine administration in type II diabetic patients. Arzneimittelforschung 1989; 39: 1451-1454.
92. Storm G., Oosterhuis B., Sollie F.A.E., Visscher H.W., Sommer W., Beitinger H., Jonkman J.H.G.: Lack of pharmacokinetic interaction between vinpocetine and oxazepam. Br. J. Clin. Pharmcol. 1994; 38: 143-146.